Aclaris Therapeutics Inc (NASDAQ:ACRS) – Analysts at Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a note issued to investors on Monday. Leerink Swann analyst S. Fernandez expects that the biotechnology company will post earnings of ($1.06) per share for the quarter. Leerink Swann has a “Outperform” rating and a $54.00 price objective on the stock. Leerink Swann also issued estimates for Aclaris Therapeutics’ Q2 2018 earnings at ($0.84) EPS, Q3 2018 earnings at ($1.16) EPS and Q4 2018 earnings at ($1.29) EPS.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.10. The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $0.80 million.
Aclaris Therapeutics (ACRS) opened at $19.86 on Wednesday. Aclaris Therapeutics has a 12-month low of $18.46 and a 12-month high of $33.10.
Hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC bought a new stake in Aclaris Therapeutics during the third quarter valued at about $142,000. Teacher Retirement System of Texas bought a new stake in Aclaris Therapeutics during the fourth quarter valued at about $200,000. Voya Investment Management LLC bought a new stake in Aclaris Therapeutics during the second quarter valued at about $247,000. Trexquant Investment LP bought a new stake in Aclaris Therapeutics during the third quarter valued at about $247,000. Finally, MetLife Investment Advisors LLC bought a new stake in Aclaris Therapeutics during the fourth quarter valued at about $244,000. 92.40% of the stock is currently owned by institutional investors.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.